Evidence map›Paper›PMID 36611252›Full record

ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2023

Relationships Between Social Vulnerability and Coronavirus Disease 2019 Vaccination Coverage and Vaccine Effectiveness.

Alexandra F Dalton, Zachary A Weber, Katie S Allen, Edward Stenehjem, Stephanie A Irving, Talia L Spark, Katherine Adams, Ousseny Zerbo, Victoria Lazariu, Brian E Dixon and 32 more

Abstract read
In one paragraph

Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Association Between Social Vulnerability and Streptococcus pneumoniae Antimicrobial Resistance in US Adults.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2024
    Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

42 authors.

Alexandra F DaltonNational Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention COVID-19 Response Team, Atlanta, Georgia, USA.ORCID 0000-0003-3407-2961
Zachary A WeberWestat, Rockville, Maryland, USA.
Katie S AllenCenter for Biomedical Informatics, Regenstrief Institute, Indianapolis, Indiana, USA.
Edward StenehjemDivision of Infectious Diseases and Clinical Epidemiology, Intermountain Healthcare, Salt Lake City, Utah, USA.
Stephanie A IrvingCenter for Health Research, Kaiser Permanente Northwest, Portland, Oregon, USA.
Talia L SparkWestat, Rockville, Maryland, USA.
Katherine AdamsNational Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention COVID-19 Response Team, Atlanta, Georgia, USA.
Ousseny ZerboKaiser Permanente Vaccine Study Center, Kaiser Permanente Northern California Division of Research, Oakland, California, USA.ORCID 0000-0002-8380-6215
Victoria LazariuWestat, Rockville, Maryland, USA.
Brian E DixonCenter for Biomedical Informatics, Regenstrief Institute, Indianapolis, Indiana, USA.
Kristin DascombDivision of Infectious Diseases and Clinical Epidemiology, Intermountain Healthcare, Salt Lake City, Utah, USA.
Emily HartmannPaso del Norte Health Information Exchange (PHIX), El Paso, Texas, USA.
Anupam B KharbandaDepartment of Pediatric Emergency Medicine, Children's Minnesota, Minneapolis, Minnesota, USA.
Toan C OngSchool of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.
Malini B DeSilvaDivision of Research, HealthPartners Institute, Minneapolis, Minnesota, USA.
Maura BeatonDepartment of Biomedical Informatics, Columbia University Irving Medical Center, New York, New York, USA.
Manjusha GaglaniBaylor Scott & White Health, Temple, Texas, USA.ORCID 0000-0002-3952-9230
Palak PatelNational Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention COVID-19 Response Team, Atlanta, Georgia, USA.
Allison L NalewayCenter for Health Research, Kaiser Permanente Northwest, Portland, Oregon, USA.
Magdalene N S KishWestat, Rockville, Maryland, USA.
Shaun J GrannisCenter for Biomedical Informatics, Regenstrief Institute, Indianapolis, Indiana, USA.
Nancy GriselDivision of Infectious Diseases and Clinical Epidemiology, Intermountain Healthcare, Salt Lake City, Utah, USA.
Chantel Sloan-AagardPaso del Norte Health Information Exchange (PHIX), El Paso, Texas, USA.ORCID 0000-0001-8959-8536
Suchitra RaoSchool of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.
Chandni RaiyaniBaylor Scott & White Health, Temple, Texas, USA.
Monica DickersonNational Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention COVID-19 Response Team, Atlanta, Georgia, USA.
Elizabeth BassettWestat, Rockville, Maryland, USA.
William F FadelCenter for Biomedical Informatics, Regenstrief Institute, Indianapolis, Indiana, USA.
Julie ArndorferDivision of Infectious Diseases and Clinical Epidemiology, Intermountain Healthcare, Salt Lake City, Utah, USA.
Juan NanezPaso del Norte Health Information Exchange (PHIX), El Paso, Texas, USA.
Michelle A BarronSchool of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.
Gabriela Vazquez-BenitezDivision of Research, HealthPartners Institute, Minneapolis, Minnesota, USA.
I Chia LiaoBaylor Scott & White Health, Temple, Texas, USA.
Eric P GriggsNational Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention COVID-19 Response Team, Atlanta, Georgia, USA.
Sarah E ReeseWestat, Rockville, Maryland, USA.
Nimish R ValviCenter for Biomedical Informatics, Regenstrief Institute, Indianapolis, Indiana, USA.
Kempapura MurthyBaylor Scott & White Health, Temple, Texas, USA.
Elizabeth A K RowleyWestat, Rockville, Maryland, USA.
Peter J EmbiCenter for Biomedical Informatics, Regenstrief Institute, Indianapolis, Indiana, USA.
Sarah BallWestat, Rockville, Maryland, USA.
Ruth Link-GellesNational Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention COVID-19 Response Team, Atlanta, Georgia, USA.ORCID 0000-0002-9617-806X
Mark W TenfordeNational Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention COVID-19 Response Team, Atlanta, Georgia, USA.

Funding

Intramural CDC HHS CC999999
6 · The paper itself

Abstract

backgroundCoronavirus disease 2019 (COVID-19) vaccination coverage remains lower in communities with higher social vulnerability. Factors such as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) exposure risk and access to healthcare are often correlated with social vulnerability and may therefore contribute to a relationship between vulnerability and observed vaccine effectiveness (VE). Understanding whether these factors impact VE could contribute to our understanding of real-world VE.

methodsWe used electronic health record data from 7 health systems to assess vaccination coverage among patients with medically attended COVID-19-like illness. We then used a test-negative design to assess VE for 2- and 3-dose messenger RNA (mRNA) adult (≥18 years) vaccine recipients across Social Vulnerability Index (SVI) quartiles. SVI rankings were determined by geocoding patient addresses to census tracts; rankings were grouped into quartiles for analysis.

resultsIn July 2021, primary series vaccination coverage was higher in the least vulnerable quartile than in the most vulnerable quartile (56% vs 36%, respectively). In February 2022, booster dose coverage among persons who had completed a primary series was higher in the least vulnerable quartile than in the most vulnerable quartile (43% vs 30%). VE among 2-dose and 3-dose recipients during the Delta and Omicron BA.1 periods of predominance was similar across SVI quartiles.

conclusionsCOVID-19 vaccination coverage varied substantially by SVI. Differences in VE estimates by SVI were minimal across groups after adjusting for baseline patient factors. However, lower vaccination coverage among more socially vulnerable groups means that the burden of illness is still disproportionately borne by the most socially vulnerable populations.

Indexed as

COVID-19AdultCOVID-19 VaccinesHumansSARS-CoV-2Social VulnerabilityVaccination CoverageVaccine EfficacyCOVID-19 VaccinesCOVID-19Social Vulnerability Indexvaccination coveragevaccine effectiveness

Identifiers

PMID36611252
PMCPMC10949185

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.